Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
ERAS-007
i
Other names:
ERAS-007, ASN007, ASN007A
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(13)
News
Trials
Company:
Asana BioSci, Erasca, UT MD Anderson Cancer Center
Drug class:
ERK2 inhibitor, ERK1 inhibitor
Related drugs:
‹
BVD-523 (17)
BAY86-9766 (16)
VTX-11e (5)
JSI-1187 (4)
ASTX029 (4)
LTT462 (3)
LY3214996 (3)
AEZS 136 (1)
D3S-002 (0)
HH2710 (0)
MK-8353 (0)
ATG-017 (0)
BVD-523 (17)
BAY86-9766 (16)
VTX-11e (5)
JSI-1187 (4)
ASTX029 (4)
LTT462 (3)
LY3214996 (3)
AEZS 136 (1)
D3S-002 (0)
HH2710 (0)
MK-8353 (0)
ATG-017 (0)
›
Associations
(13)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3) (NCT05039177)
Phase 1/2
Erasca, Inc.
Erasca, Inc.
Active, not recruiting
Phase 1/2
Erasca, Inc.
Active, not recruiting
Last update posted :
02/11/2025
Initiation :
09/20/2021
Primary completion :
08/01/2025
Completion :
12/01/2025
KRAS • BRAF • NRAS
|
BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600
|
Erbitux (cetuximab) • Ibrance (palbociclib) • Braftovi (encorafenib) • ERAS-007
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC (HERKULES-2) (NCT04959981)
Phase 1b
Erasca, Inc.
Erasca, Inc.
Completed
Phase 1b
Erasca, Inc.
Completed
Last update posted :
07/25/2023
Initiation :
09/02/2021
Primary completion :
04/27/2023
Completion :
04/27/2023
KRAS
|
KRAS mutation • EGFR mutation • KRAS G12C
|
Tagrisso (osimertinib) • Lumakras (sotorasib) • ERAS-007 • ERAS-601
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies (HERKULES-4) (NCT05279859)
Phase 1b/2
Erasca, Inc.
Erasca, Inc.
Withdrawn
Phase 1b/2
Erasca, Inc.
Withdrawn
Last update posted :
06/15/2022
Initiation :
03/15/2022
Primary completion :
03/01/2025
Completion :
06/01/2025
FLT3
|
FLT3 mutation
|
Xospata (gilteritinib) • ERAS-007 • ERAS-601
A Study of ASN007 in Patients With Advanced Solid Tumors (NCT03415126)
Phase 1
Asana BioSciences
Asana BioSciences
Completed
Phase 1
Asana BioSciences
Completed
Last update posted :
07/09/2020
Initiation :
01/19/2018
Primary completion :
06/30/2020
Completion :
06/30/2020
KRAS • HRAS
|
KRAS mutation • BRAF mutation • NRAS mutation • HRAS mutation
|
ERAS-007
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login